Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension

Thyroid

Volumn 22, Issue 6, 2012, Pages 575-584

  Ricarte Filho, Julio ^a   Ganly, Ian ^a   Rivera, Michael ^a   Katabi, Nora ^a   Fu, Weimin ^a   Shaha, Ashok ^a   Tuttle, R Michael ^a   Fagin, James A ^a   Ghossein, Ronald ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; RADIOACTIVE IODINE;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CERVICAL LYMPH NODE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SPECIFIC SURVIVAL; FATALITY; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MEDICAL RECORD REVIEW; ONCOGENE; PREDICTOR VARIABLE; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SURVIVAL PREDICTION; THYROID CARCINOMA;

CARCINOMA; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; IODINE RADIOISOTOPES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROID NEOPLASMS;

EID: 84861988936     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0431     Document Type: Article

References (27)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, Mclver B, Pacini F, Schlumberger M, Sherman SI, Stewart DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
2. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) 2010 AJCC Cancer Staging Manual, 7th edition. Springer, New York, NY, pp 67-74.
3. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM 2010 Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 148:1100-1106; discussion 1006-1007.
4. Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso JD, Al Ghuzlan A, Chami L, Schlumberger M, Travagli JP 2009 Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 94:1162-1167.
5. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system. Thyroid 20:1341-1349.
6. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (eds) 2007 SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD.
7. Bardet S, Malville E, Rame JP, Babin E, Samama G, De Raucourt D, Michels JJ, Reznik Y, Henry-Amar M 2008 Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol 158:551-560. (Pubitemid 351606351)
8. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, Travagli JP, Schlumberger M 2005 Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90:5723-5729. (Pubitemid 41415482)
9. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A 2004 A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135:139-148. (Pubitemid 38130764)
10. Cranshaw IM, Carnaille B 2008 Micrometastases in thyroid cancer. An important finding? Surg Oncol 17:253-258.
11. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) 2004 World Health Organization Classification of Tumours. Pathology & Genetics Tumours of the Endocrine Organs. IARC Press, Lyon.
12. Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, Shah JP, Singh B, Ghossein RA 2006 Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106:1286-1295. (Pubitemid 43363905)
13. Rosai J, Carcangiu ML, Delellis RA 1992 Tumors of the thyroid gland In: Rosai J, Sobin LH (eds) Atlas of Tumor Pathology, vol. 5. Armed Forces Institute of Pathology, New York, pp 161-182.
14. Ricarte-Filho JCM, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3- CA and AKT1. Cancer Res 69:4885-4893.
15. Imkamp F, von Wasielewski R, Musholt TJ, Musholt PB 2007 Rearrangement analysis in archival thyroid tissues: punching microdissection and artificial RET/PTC 1-12 transcripts. J Surg Res 143:350-363. (Pubitemid 350101558)
16. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE 2006 Correlation between genetic alterations and microscopic features. Clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-222. (Pubitemid 43740191)
17. Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle RM, Fagin JA, Ghossein RA 2010 Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histologic subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23:1191-1200.
18. V600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66:6521-6529.
19. V600E mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 15:191-205.
20. Ito Y, Fukushima M, Tomoda C, Inoue H, Kihara M, Higashiyama T, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A 2009 Prognosis of patients with papillary thyroidcarcinoma having clinically apparent metastasis to the lateral compartment. Endocr J 56:759-766.
21. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK 2006 The BRAF mutation is useful for prediction of clinicalrecurrence in lowrisk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 65:364-368.
22. Jung CK, Kang YG, Bae JS, Lim DJ, Choi YJ, Lee KY 2010 Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 23:1201-1208.
23. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A 2007 The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer. Ann Surg 246:466-471.
24. V600E mutation and the biology of papillary thyroid cancer. Endocr-Relat Cancer 15:191-205.
25. Sykorova V, Dvorakova S, Ryska A, Vcelak J, Vaclavikova E, Laco J, Kodetova D, Kodet R, Cibula A, Duskova J, Hlobilkova A, Astl J, Vesely D, Betka J, Hoch J, Smutny S, Cap J, Vlcek P, Novak Z, Bendlova B 2010 BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest 33:318-324.
26. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA 2011 Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30:3154-3162.
27. Xing M 2010 Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321:86-93.